Enhanced Efficacy of Post-Procedural Skin Care: A Double-Blind, Randomized, Vehicle-Controlled, Split-Face Clinical Study Assessing a Novel Neuropeptide Serum Following Botulinum Toxin Injection
Clinical, Cosmetic and Investigational Dermatology · 2026-06 · Volume 19 · 1-9
DOI: 10.2147/ccid.s581831 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-06. Verfasst von Mark Lupin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cosmedica The Laser Centre, Victoria, BC, Canada. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cosmedica The Laser Centre, Victoria, BC, Canada.
- MedSpa, Victoria, BC, Canada.
- SkinCeuticals, New York, NY, USA.
ORCID-Profile: Mark Lupin
Zitieren
APA
Lupin, M., Brieva, P., Dayeh, N. R., & White, S. (2026). Enhanced Efficacy of Post-Procedural Skin Care: A Double-Blind, Randomized, Vehicle-Controlled, Split-Face Clinical Study Assessing a Novel Neuropeptide Serum Following Botulinum Toxin Injection. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-9. https://doi.org/10.2147/ccid.s581831
Vancouver
Lupin M, Brieva P, Dayeh NR, White S. Enhanced Efficacy of Post-Procedural Skin Care: A Double-Blind, Randomized, Vehicle-Controlled, Split-Face Clinical Study Assessing a Novel Neuropeptide Serum Following Botulinum Toxin Injection. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-9. doi:10.2147/ccid.s581831
BibTeX
@article{Lupin2026,
author = {Lupin, Mark and Brieva, Patricia and Dayeh, Nour R and White, Stacy},
title = {Enhanced Efficacy of Post-Procedural Skin Care: A Double-Blind, Randomized, Vehicle-Controlled, Split-Face Clinical Study Assessing a Novel Neuropeptide Serum Following Botulinum Toxin Injection},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--9},
doi = {10.2147/ccid.s581831}
}
EUVIMED